220 related articles for article (PubMed ID: 33382957)
1. Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody.
Falck D; Thomann M; Lechmann M; Koeleman CAM; Malik S; Jany C; Wuhrer M; Reusch D
MAbs; 2021; 13(1):1865596. PubMed ID: 33382957
[TBL] [Abstract][Full Text] [Related]
2. Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model.
Falck D; Lechmann M; Momčilović A; Thomann M; Koeleman CAM; Jany C; Malik S; Wuhrer M; Reusch D
MAbs; 2022; 14(1):2145929. PubMed ID: 36383465
[TBL] [Abstract][Full Text] [Related]
3. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans.
Yu M; Brown D; Reed C; Chung S; Lutman J; Stefanich E; Wong A; Stephan JP; Bayer R
MAbs; 2012; 4(4):475-87. PubMed ID: 22699308
[TBL] [Abstract][Full Text] [Related]
4. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
5. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development.
Kaur H
Crit Rev Biotechnol; 2021 Mar; 41(2):300-315. PubMed ID: 33430641
[TBL] [Abstract][Full Text] [Related]
6. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.
Goetze AM; Liu YD; Zhang Z; Shah B; Lee E; Bondarenko PV; Flynn GC
Glycobiology; 2011 Jul; 21(7):949-59. PubMed ID: 21421994
[TBL] [Abstract][Full Text] [Related]
7. Glycoform-resolved FcɣRIIIa affinity chromatography-mass spectrometry.
Lippold S; Nicolardi S; Domínguez-Vega E; Heidenreich AK; Vidarsson G; Reusch D; Haberger M; Wuhrer M; Falck D
MAbs; 2019 Oct; 11(7):1191-1196. PubMed ID: 31276431
[TBL] [Abstract][Full Text] [Related]
8. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
9. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
10. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
[TBL] [Abstract][Full Text] [Related]
11. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.
Hills AE; Patel A; Boyd P; James DC
Biotechnol Bioeng; 2001 Oct; 75(2):239-51. PubMed ID: 11536148
[TBL] [Abstract][Full Text] [Related]
12. Cell Free Remodeling of Glycosylation of Antibodies.
Mota LM; Tayi VS; Butler M
Methods Mol Biol; 2022; 2370():117-146. PubMed ID: 34611867
[TBL] [Abstract][Full Text] [Related]
13. LC/MS Assessment of Glycoform Clearance of A Biotherapeutic MAb in Rabbit Ocular Tissues.
Dong S; Chen L; Sauer A; Dittus L
J Pharm Sci; 2023 Aug; 112(8):2285-2291. PubMed ID: 37062414
[TBL] [Abstract][Full Text] [Related]
14. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
Liu L
J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
[TBL] [Abstract][Full Text] [Related]
15. Benchmarking glycoform-resolved affinity separation - mass spectrometry assays for studying FcγRIIIa binding.
Gstöttner C; Lippold S; Hook M; Yang F; Haberger M; Wuhrer M; Falck D; Schlothauer T; Domínguez-Vega E
Front Immunol; 2024; 15():1347871. PubMed ID: 38469305
[TBL] [Abstract][Full Text] [Related]
16. Analysis of NIST Monoclonal Antibody Reference Material Glycosylation Using the LC-MS/MS-Based Glycoproteomic Approach.
Zhao J; Peng W; Dong X; Mechref Y
J Proteome Res; 2021 Jan; 20(1):818-830. PubMed ID: 33196194
[TBL] [Abstract][Full Text] [Related]
17. High-Throughput Analysis of IgG Fc Glycopeptides by LC-MS.
Falck D; Jansen BC; de Haan N; Wuhrer M
Methods Mol Biol; 2017; 1503():31-47. PubMed ID: 27743357
[TBL] [Abstract][Full Text] [Related]
18. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
[TBL] [Abstract][Full Text] [Related]
19. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
[TBL] [Abstract][Full Text] [Related]
20. Impact of Fc N-linked glycans on in vivo clearance of an immunoglobulin G1 antibody produced by NS0 cell line.
Kim J; Luo H; White W; Rees W; Venkat R; Albarghouthi M
MAbs; 2020; 12(1):1844928. PubMed ID: 33171078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
